Microbiology

David Lubaroff, PhD

Portrait

Professor of Urology
Professor of Microbiology

Contact Information

Office: 3210 MERF
Iowa City, IA 52242
Office Phone: 319-335-8423

Email: david-lubaroff@uiowa.edu

Education

BS, University of the Sciences in Philadelphia
MS, Georgetown University
PhD, Yale University

Education/Training Program Affiliations

Biosciences Graduate Program
Free Radical and Radiation Biology Graduate Program

Research Summary

The work in the Lubaroff concentrates on the area of tumor immunology with an emphasis on immunotherapy. We have constructed microbial vaccines to be used for the investigation of gene and immunotherapy of prostate cancer. Investigations on the ability of immunized animals to produce immune responses to the transgene product induced by the vaccine are underway. Both in vitro and in vivo experiments are being carried out, the latter studies involve the destruction of tumors following immunization of animals with the prostate cancer vaccine. The mechanisms of tumor rejection induced by the vaccines are being studied using methodologies to deplete specific cell populations, and by the use of transgenic mice. We are also investigating the ability of unmethylated CpG oligodinucleotides to augment the anti-tumor immune responses. Additionally, we are carrying our "translational" research in the form of clinical trials of our adenovirus vaccine in men with prostate cancer. Important in these trials is the safety of the vaccine and its ability to induce anti-tumor immunity. We have recently completed a Phase I clinical trial of the vaccine that demonstrated its safety. We have evaluated the immunity induced by the vaccine using measures of antibodies, cytotoxic T lymphocytes, and number of antigen-specific T cells using both intracellular cytokine staining and ELISPOT analysis. A therapeutic Phase II trial will begin shortly. Finally, we have been collaborating on studies of psychosocial effects on immune status in cancer patients.

Selected Publications

Lubaroff D.  Prostate cancer vaccines in clinical trials.  Expert Rev Vaccines.  2012. 11:857-68.
[Link]

Lemke C, Graham J, Geary S, Zamba G, Lubaroff D, Salem A.  Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.  Mol Pharm.  2011. 8:1652-61.
[Link]

Lemke C, Graham J, Lubaroff D, Salem A.  Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse.  Prostate Cancer Prostatic Dis.  2011. 14:118-21.
[Link]

Geary S, Lemke C, Lubaroff D, Salem A.  Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.  Cancer Immunol Immunother.  2011. 60:1309-17.
[Link]

Lubaroff D, Konety B, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisely J, Boeglin D, Ratliff T, Williams R.  Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.  Clin Cancer Res.  2009. 15:7375-80.
[Link]

Date Last Modified: 07/31/2013 - 10:51:40